Aims LDL cholesterol (LDL-C) is the current lipid standard for cardiovascular disease (CVD)-risk assessment in type 1 diabetes. Apolipoprotein B (apoB) may be helpful to further stratify CVD risk. We explored the association between apoB and pulse wave velocity (PWV) to determine if apoB would improve CVD-risk stratification, especially in type 1 diabetes adolescents with borderline LDL-C (100-129 mg/dL). We hypothesized that type 1 diabetes adolescents with borderline LDL-C and elevated apoB (C90 mg/dL) would have increased PWV compared to those with borderline LDL-C and normal apoB (\90 mg/dL), and that apoB would explain more of the variability of PWV than alternative lipid indices. Methods Fasting lipids, including apoB, were collected in 267 adolescents, age 12-19 years, with diabetes duration [5 years and HbA1c 8.9 ± 1.6 %. Triglyceride to HDL-C ratio (TG/HDL-C) and nonHDL-cholesterol (nonHDL-C) were calculated. PWV was measured in the carotid-femoral segment. Results ApoB, nonHDL-C and TG/HDL-C correlated with PWV (p \ 0.0001). ApoB, nonHDL-C and TG/HDL-C remained significantly associated with PWV in fully adjusted models. In adolescents with borderline LDL-C (n = 61), PWV was significantly higher in those with elevated apoB than in those with normal apoB (5.6 ± 0.6 vs. 5.2 ± 0.6 m/s, p \ 0.01) and also remained significant after adjustment for CVD-risk factors (p = 0.0002). Moreover, in those with borderline LDL-C, apoB explained more of the variability of PWV than nonHDL-C and TG/ HDL-C. Conclusion Elevated apoB is associated with increased arterial stiffness in type 1 diabetes adolescents. Measurement of apoB in addition to LDL-C may be helpful in stratifying CVD risk in type 1 diabetes adolescents, especially in those with borderline LDL-C.
Introduction
Cardiovascular disease (CVD) is the primary cause of mortality in patients with type 1 diabetes [1] . Dyslipidemia is one of the major contributory factors for CVD in type 1 diabetes [2] [3] [4] . It is increasingly recognized that atherosclerosis begins early in life in association with dyslipidemia and tracks into adulthood [5, 6] . Almost a third of children and adolescents with type 1 diabetes demonstrate dyslipidemia [2] . Despite the robust evidence of dyslipidemia as a major risk factor for the development of CVD, the literature suggests significant under-treatment of this risk factor for children and adolescents with type 1 diabetes [2, 3, 7] . Only 65 % of participants of the T1D Exchange study met the American Diabetes Association's (ADA) targets for LDL-C [8] .
Low-density lipoprotein cholesterol (LDL-C) remains the primary lipid marker of CVD risk in adolescents and adults with type 1 diabetes [5, 6, 9, 10] . Data from the SEARCH for Diabetes in Youth (SEARCH) study showed that approximately one-third of youth with type 1 diabetes had LDL-C in the borderline range (100-129 mg/dL) [7] , which is associated with less clear CVD risk and more ambiguous treatment recommendations. Studies have shown that apolipoprotein B (apoB) may add to current predictors of CVD and peripheral arterial disease [11] [12] [13] . The SEARCH case-control study showed that apoB levels were elevated in type 1 diabetes compared to nondiabetic controls independent of HbA1c or LDL-C [12, 14] . For that reason, measurement of apoB in addition to LDL-C may help reclassify CVD risk in type 1 diabetes adolescents with borderline LDL-C levels and also determine when lipid-lowering treatment should be considered. Accordingly, our aim of this study was to investigate whether apoB was associated with pulse wave velocity (PWV), a measure of arterial stiffness that has been shown to be a strong predictor of CVD [15] , in adolescents with type 1 diabetes. We hypothesized that there would be an independent association between apoB and PWV. Second, we hypothesized that among adolescents with type 1 diabetes and borderline LDL-C (100-129 mg/ dL), patients with elevated apoB (C90 mg/dL) would have higher PWV compared to those with normal apoB levels (\90 mg/dL). Finally, we hypothesized that apoB would explain more variability of PWV than nonHDLcholesterol (nonHDL-C) and the ratio of triglycerides to HDL-C (TG/HDL-C) in adolescents with type 1 diabetes and borderline LDL-C.
Patients and methods
The Determinants of Macrovascular Disease in Adolescents with Type 1 Diabetes study was initiated to investigate atherosclerotic disease risk in youth with type 1 diabetes [16] . The study enrolled subjects aged 12-19 years from 2008 to 2010, with type 1 diabetes. Study participants with type 1 diabetes were diagnosed by islet cell antibody or by provider clinical diagnosis, had diabetes duration [5 years at entry into the study, and received care at the Barbara Davis Center for Childhood Diabetes. All subjects (n = 267) with type 1 diabetes and data available for fasting lipids, apoB and PWV were included in this analysis. The study was approved by the Colorado Multiple Institution Review Board, and informed consent and assent (for subjects \18 years) were obtained from all subjects.
Pubertal status was evaluated by Tanner staging by a study investigator or clinical provider [17] . After subjects had been laying supine for a minimum of 5 min, blood pressure measurements were obtained using a Dynapulse 5200A (Pulse Metric, San Diego, California), and three measurements were averaged. Pulse pressure calculated as the difference between the systolic blood pressure (SBP) and diastolic pressure (DBP). Height was measured to the nearest 0.1 cm with shoes removed using a wall-mounted stadiometer, and weight was measured to the nearest 0.1 kg using a Detecto scale (Detecto, Webb City, Missouri). BMI z-score was calculated using the 2000 Centers for Disease Control and Prevention growth chart standards. Participants were asked about smoking status, and current smoking is included in the analysis.
All subjects fasted overnight (C8 h) and were asked to refrain from caffeine intake and smoking within 8 h prior to the study visit (due to potential effects on vascular measures). Urine samples were collected, and urine creatinine and albumin were measured (RIA, Diagnostic Products). Microalbuminuria was defined as albumincreatinine ratio (ACR) C30 mg/g. HbA1c was measured on the DCA Advantage by Siemens (Princeton, New Jersey) at the Children's Hospital Colorado main clinical lab. Total cholesterol, high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) were performed in the Clinical Translational Research Core lab using a Beckman Coulter AU system (Beckman Coulter Inc, Brea, CA). LDL-C was calculated using the Friedwald formula (no subjects with TG [400 mg/dL), and apoB was measured by Beckman Array Nephelometer (Beckman Coulter Inc, Brea, CA) with an intra-and inter-assay coefficients of variation of 1.1 and 5.4 %, respectively. NonHDL-C was calculated by subtracting HDL-C from total cholesterol, and the ratio of TG to HDL-C was calculated by dividing TG by HDL-C. LDL-C levels were defined as elevated (C130 mg/dL), borderline (100-129 mg/dL) and normal (\100 mg/dL) based on American Diabetes Association (ADA) guidelines [18] . Elevated nonHDL-C was defined as C130 mg/dL, and normal nonHDL-C was defined as \130 mg/dL, and elevated apoB was defined as C90 mg/dL, and normal apoB was defined as\90 mg/dL according to the ADA and American College of Cardiology (ACC) position statement [19] .
Pulse wave velocity (PWV) was measured in the carotid-femoral segment using arterial tonometry with the SphygmoCor Vx (AtCor Medical, Lisle, IL). The carotid to femoral path length was measured from the reference point of the lowest portion of the sternal notch to the femoral pulse. The average of three measurements was entered into the SphygmoCor software. While recording a 3-lead ECG, pulse wave was recorded using arterial tonometry, first at carotid, followed by recording of pulse wave at femoral. The two pulse waves are subsequently compared using the R-wave as a reference, allowing us to compare the time from the R-wave to the foot of pulse waves, and to calculate PWV in meters per second (m/s). PWV measures were repeated in a subset of subjects to measure variability in the measure. For the 15 subjects with quality control data (repeated PWV measurements) at baseline, strong intraclass correlations were observed between the three PWV measures with an intraclass correlation coefficient (ICC) calculated at 0.91 [20] .
Statistical analysis
Analyses were performed in SAS (version 9.3 or higher; SAS Institute, Cary, NC). Demographic and clinical characteristics among type 1 diabetes adolescents with normal, borderline and elevated LDL-C were compared using ANOVA for parametric variables and Kruskal-Wallis for nonparametric variables (Table 1) . Furthermore, characteristics in type 1 diabetes adolescents with borderline LDL-C were compared in those with normal apoB levels to those with elevated apoB using Chi-square tests for parametric categorical variables and t test for continuous variables (Table 2 ). Wilcoxon rank sum was employed for TG and TG/HDL-C due to their nonparametric distribution. TG and TG/HDL-C were natural log-transformed for further analyses. Pearson correlations were performed to calculate correlation coefficients for CVD-risk factors (age, gender, BMI-z, HbA1c, HDL-C, LDL-C, lnTG, lnTG/ HDL-C, apoB, nonHDL-C, DBP, SBP, ACR and smoking status) and PWV.
Multivariable linear regression models were employed to determine which variable remained significantly associated with PWV. Variables included in the multivariable models were based on a priori criteria: significance in previous work, significant contribution to the model (p value of \0.1), or confounding between the main variable of interest and the outcome by [10 %. In addition to including apoB, nonHDL-C and lnTG/HDL-C, one at a 
Acta Diabetol (2015) 52:611-619 613 time, the following variables were included in the fully adjusted models: age, sex, Tanner stage, BMI z-score, HbA1c, SBP, DBP and smoking status. We also reran the models excluding the three subjects on lipid-lowering medications. We included squared partial correlation coefficients and tolerance to further examine the proportion of the variance of PWV explained by the independent variables. We also ran similar models exploring the associations between apoB, nonHDL-C and TG/HDL-C, respectively, with PWV in adolescents with borderline LDL-C. We compared age, sex and Tanner stage-adjusted PWV for subjects divided into four groups: (1) subjects with normal LDL-C and normal apoB; (2) subjects with borderline LDL-C and normal apoB; (3) subjects with borderline LDL-C and elevated apoB; and (4) subjects with elevated LDL-C and apoB (Fig. 1) . ANOVA tests were used to calculate adjusted least square mean ± SD of PWV stratified by LDL-C and apoB groups.
Data are presented as mean ± SD for continuous variables, median and IQR for continuous variables with nonparametric distribution or count and percent for categorical variables. Correlation data are presented as r coefficient, linear regression data are presented as b ± SE, and squared partial correlation data are presented as R 2 . Significance was based on an a-level of 0.05.
Results
Subject characteristics stratified by LDL-C concentration for adolescents with type 1 diabetes are shown in Table 1 . Most subjects were post-pubertal, with a mean age of 15.4 ± 2.2 years, and 80 % of subjects had Tanner PWV was significantly higher in subjects with elevated apoB compared to those with normal apoB levels (5.7 ± 0.7 vs. 5.2 ± 0.6 m/s, p \ 0.0001). Subjects with elevated apoB were also older than subjects with normal apoB (16.0 ± 2.1 vs. 15.2 ± 2.1 years, p = 0.02), had higher HbA1c (10.1 ± 1.8 % vs. 8.6 ± 1.3 %, p \ 0.0001), higher LDL-C (121 ± 29 vs. 79 ± 17 mg/ dL, p \ 0.0001), higher TG (108 vs. 69 mg/dL, p \ 0.0001), higher DBP (72 ± 6 vs. 67 ± 6 mm Hg, Fig. 1 Age, sex and Tanner-adjusted PWV in adolescents with type 1 diabetes by LDL-C and apoB. Age, sex and Tanner stage-adjusted means for PWV in adolescents with normal LDL-C and apoB, borderline LDL-C and normal apoB, borderline LDL-C and elevated apoB and elevated LDL-C and elevated apoB. Adjusted PWV in adolescents with borderline LDL-C and normal apoB was not significantly different from those with normal LDL-C and normal apoB (p = 0.34). Adjusted PWV in adolescents with borderline LDL-C and elevated apoB was significantly higher than in those with borderline LDL-C and normal apoB (p \ 0.0001). The difference between in adjusted PWV between adolescents with elevated LDL-C and apoB compared to those with borderline LDL-C and elevated apoB was not statistically significant (p = 0.08) p \ 0.0001) and higher SBP (116 ± 8 vs. 113 ± 9, p = 0.02). The difference in PWV remained significant after adjusting for Tanner stage, age, sex, DBP, BMI zscore and HbA1c (5.5 ± 0.6 vs. 5.2 ± 0.6 m/s, p \ 0.0001).
Of the adolescents with borderline LDL-C (n = 61), 57 % (n = 35) had elevated apoB. For these subjects, PWV was significantly higher compared to those with normal apoB levels (n = 26) (5.6 ± 0.6 vs. 5.2 ± 0.6 m/s, p \ 0.01, Table 2 ). Subjects with borderline LDL-C and elevated apoB had similar age, sex, BMI z-score distribution and higher HbA1c, total cholesterol, LDL-C and TG than those with borderline LDL-C and normal apoB levels ( Table 2) .
When we examined age, sex and Tanner stage-adjusted PWV by LDL-C and apoB in adolescents with type 1 diabetes (Fig. 1) , subjects with normal LDL-C and normal apoB had similar mean PWV compared to subjects with borderline LDL-C and normal apoB (5.2 ± 1.0 vs. 5.0 ± 0.6 m/s, p = 0.34). In contrast, subjects with borderline LDL-C and elevated apoB had significantly higher PWV (5.6 ± 0.7 m/s) than either of the groups with normal apoB (p \ 0.0001). Subjects with elevated LDL-C and apoB had the highest mean PWV (5.9 ± 0.6 m/s), but there was no significant difference in PWV between subjects with borderline LDL-C and elevated apoB and subjects with elevated LDL-C and elevated apoB (p = 0.08).
In separate linear regression models, apoB (b ± SE: 0.006 ± 0.002, p = 0.0002), nonHDL-C (b ± SE: 0.005 ± 0.001, p = 0.0001) and lnTG/HDL-C (b ± SE: 0.17 ± 0.07, p = 0.01) individually remained significantly associated with PWV after adjusting for age, sex, Tanner stage, BMI z-score, SBP, DBP, HbA1c and smoking status (Table 3 ). In subjects with borderline LDL-C, the association between apoB and PWV (p = 0.01) also remained significant in a fully adjusted multivariable model, but not for nonHDL-C (p = 0.09) and lnTG/HDL-C (p = 0.15, Table 3 ). Furthermore, apoB (R 2 = 13 %) explained more of the variability of PWV in subjects with borderline LDL-C than nonHDL-C (R 2 = 6 %), TG/HDL-C (R 2 = 4 %) and conventional risk factors like HbA1c (R 2 = 4 %), SBP (R 2 = 3 %) and DBP (R 2 = 8 %). We also reran the models without the three subjects on statins which did not change the significance of any of our findings.
Based on the above data, apoB appears to be more strongly related to PWV than nonHDL-C and lnTG/HDL-C in adolescents with borderline LDL-C. For that reason, with PWV as a surrogate for CVD risk, 43 % of the adolescents with borderline LDL-C could be reclassified as low risk based on normal levels of apoB, and the remaining 57 % with elevated apoB could be classified as high risk for CVD (Fig. 2) .
Discussion
In the cohort, we examined almost one-fourth of adolescents with type 1 diabetes had borderline LDL-C and of those, over half had elevated apoB. Those with elevated apoB demonstrated significantly higher arterial stiffness as measured by PWV, and the association between apoB and PWV remained significant after adjusting for other CVDrisk factors. Moreover, apoB was a stronger determinant of PWV than nonHDL-C, lnTG/HDL-C and conventional risk factors for adolescents with type 1 diabetes and borderline LDL-C in our study. This suggests that measurement of apoB in addition to LDL-C may be helpful to better stratify PWV has emerged as a useful tool to evaluate vascular health [15, 21, 22] and a predictor of future CV events and all-cause mortality [15] . It has been reported that children and adolescents with type 1 diabetes have increased arterial stiffness compared to healthy controls [23] . It has been demonstrated that apoB at baseline is predictive of PWV measured 6 years later in healthy young adults [11] , but no studies to date have examined the association between apoB and PWV in adolescents with type 1 diabetes.
There are extensive data demonstrating a relationship between LDL-C and atherosclerosis, but focusing only on LDL-C may not be adequate for patients with type 1 diabetes. A significant proportion of adult type 1 diabetes patients with CVD have LDL-C in the normal range [24, 25] . One possible explanation for this discrepancy is the mismatch that has been described between the LDL-C and the number of atherogenic lipid particles. Moreover, LDL-C, nonHDL-C and apoB carry unique lipid information [26] . LDL-C represents the cholesterol content of LDL, intermediate-density lipoprotein and lipoprotein (a), whereas nonHDL-C is the LDL cholesterol and cholesterol content of circulating VLDL. ApoB directly measures the aggregate number of all atherogenic lipoproteins since each atherogenic particle contains one apoB molecule. Therefore, apoB may provide a more complete picture of the lipoprotein profile as it will account for small, dense and more atherogenic particles [27] . Elevated apoB is also one of the most frequent lipid abnormalities in children and adolescents with type 1 diabetes [14] .
The associations of apoB and nonHDL-C with CVD risk are well described in the literature, but are not without controversy. Most studies, but not all [28, 29] , have demonstrated that apoB and nonHDL-C are more closely associated with CVD risk and all-cause mortality in adults than LDL-C [30] [31] [32] [33] [34] . Moreover, TG/HDL-C has been shown to be an independent determinant of arterial stiffness in obese youth [35] . It remains unclear; however, whether apoB is superior to nonHDL-C and TG/HDL-C for CVD-risk prediction [29, 36, 37] , but our data suggest that apoB is more strongly related to PWV in adolescents with type 1 diabetes and borderline LDL-C. Consistent with our findings, Mora et al. [38] recently reported in the Women's Health Study, that when LDL-C and apoB were discordant LDL-C under-or overestimated coronary risk by 20-50 %, and the coronary risk was greatest when apoB and LDL-C were concordant (both greater or equal to median levels of cohort).
The Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents and the ADA do not yet recommend apoB for universal lipid screening in children and adolescents with or without type 1 diabetes [18, 39] . Previous publications have suggested that apoB and other cholesterol indices should be considered to be complementary rather than competitive indices in adults with type 1 diabetes [40] , and that it is useful to measure both apoB and LDL-C, especially when considering lipid-lowering therapy [41] . ApoB and LDL-C have been shown to be most concordant at their extremes (the highest and lowest quintiles of each) [42] , so the use of both may be especially useful for values that are borderline.
There are important limitations to the present study worth mentioning. This study had an observational design and cross-sectional analysis without CVD endpoints (e.g., myocardial infarction) which would have been difficult to obtain in our adolescent cohort unless the participants were Fig. 2 Reclassification of CVD-risk in type 1 diabetes adolescents with borderline LDL-C. Adolescents with type 1 diabetes were grouped according to LDL-C (normal, borderline and elevated) and apoB (normal and elevated). Approximately one-quarter of participants had borderline LDL-C, and of those participants, 43 % had normal apoB and not significantly different adjusted PWV to those with normal LDL-C/normal apoB (Fig. 1) . Similarly, 57 % of the participants with borderline LDL-C had elevated apoB and not significantly different adjusted PWV from those with elevated LDL-C/elevated apoB (Fig. 1) . Using PWV as a surrogate for cardiovascular disease (CVD), apoB can be used to stratify CVD risk in adolescents with type 1 diabetes and borderline LDL-C followed up for several decades. Although we adjusted for a variety of important confounding variables, we cannot rule out the presence of unknown risk factors that may have biased the present analyses. There are generally no standardized cutoffs for elevated PWV in the pediatric and adolescent age groups, and without a dichotomous outcome, we were unable to perform conventional prediction performance analyses (e.g., C-statistics). Our cohort is also predominantly nonHispanic white (81 %), but this is consistent with the type 1 diabetes population in Colorado. The majority of our subjects were post-pubertal (80 %) implying that our findings may not be applicable to prepubertal adolescents with type 1 diabetes; however, pharmacologic treatment of dyslipidemia in prepubertal children has been reserved for extremely elevated LDL-C. Adjusting for Tanner stage did not change the association between apoB and PWV. Furthermore, the lack of a significant difference in PWV between subjects with borderline LDL-C and elevated apoB and subjects with elevated LDL-C and apoB may be due to our limited sample size. While an association between apoB and PWV was observed, the relationship of apoB with future changes in arterial stiffness is unknown. Finally, as only three subjects were taking statins, we did not have sufficient power for any meaningful analysis with statin use, but excluding these subjects from our analyses did not change the significance of our findings. While these data suggest that apoB may help stratify risk and identify patients who might benefit from statin therapy, such treatment remains rare in the adolescent T1D population.
In summary, dyslipidemia is common in children and adolescents with type 1 diabetes and contributes to increased risk of developing CVD. The literature indicates that dyslipidemia is undertreated in children and adolescents with type 1 diabetes [2, 3, 7] , which may be partly due to a significant proportion of subjects in this age group having borderline LDL-C where CVD risks are less clear. We report significantly higher arterial stiffness in adolescents with type 1 diabetes, borderline LDL-C (100-129 mg/dL) and elevated apoB (C90 mg/dL) than those with borderline LDL-C and normal apoB. Moreover, the association between apoB and PWV appears to be independent of other known CVD-risk factors. One potential means of improving CVD outcomes in type 1 diabetes is more precise estimation of dyslipidemia. Evaluation of apoB in adolescents with type 1 diabetes and borderline LDL-C could lead to better risk stratification and more aggressive treatment with lipid-lowering medications in those in the highest risk category. Further research is needed, particularly longitudinal studies, to determine if apoB should be added to current lipid screening recommendations for adolescents with type 1 diabetes.
